Mental Health Resource Use Among Patients Undergoing Curative Intent Treatment for Bladder Cancer.
Journal
Journal of the National Cancer Institute
ISSN: 1460-2105
Titre abrégé: J Natl Cancer Inst
Pays: United States
ID NLM: 7503089
Informations de publication
Date de publication:
04 09 2021
04 09 2021
Historique:
received:
27
08
2020
revised:
18
12
2020
accepted:
22
02
2021
pubmed:
7
3
2021
medline:
25
2
2022
entrez:
6
3
2021
Statut:
ppublish
Résumé
Patients with bladder cancer may experience mental health distress. Mental health-care service (MHS) use can quantify the magnitude of the problem. The Ontario Cancer Registry was used to identify all patients with bladder cancer treated with curative-intent cystectomy or radiotherapy in Ontario, Canada (2004-2013). Population-level databases were used to identify MHS use (visits to general practitioner, psychiatrist, emergency department, or hospitalization). Generalized estimating equations were used to compare rates of MHS use. Baseline, peritreatment, and posttreatment MHS use were defined as visits from 2 years to 3 months before, 3 months before to 3 months after, and from 3 months after to 2 years after start of treatment, respectively. From 2004 to 2013, 4296 patients underwent cystectomy (n = 3332) or curative-intent radiotherapy (n = 964). Compared with baseline, the rate of MHS use was higher in the peritreatment (adjusted rate ratio [aRR] = 1.64, 95% confidence interval [CI] = 1.48 to 1.82) and posttreatment periods (aRR = 1.45, 95% CI =1.30 to 1.63). By 2 years posttreatment, 24.6% (95% CI = 23.4% to 25.9%) of all patients had MHS use. Patients with baseline MHS use had substantially higher MHS use in the peritreatment (aRR = 5.77, 95% CI = 4.86 to 6.86) and posttreatment periods (aRR = 4.58, 95% CI = 3.78 to 5.55). Female patients had higher use MHS use overall, but males had a higher incremental increase in the posttreatment period compared with baseline (2-sided Pinteraction = .02). Male patients had a statistically significant increase in MHS use following surgery or radiotherapy, whereas female patients only had an increase following surgery. MHS use is common among patients undergoing treatment for bladder cancer, particularly in the peritreatment period. Screening for mental health concerns in this population is warranted.
Sections du résumé
BACKGROUND
Patients with bladder cancer may experience mental health distress. Mental health-care service (MHS) use can quantify the magnitude of the problem.
METHODS
The Ontario Cancer Registry was used to identify all patients with bladder cancer treated with curative-intent cystectomy or radiotherapy in Ontario, Canada (2004-2013). Population-level databases were used to identify MHS use (visits to general practitioner, psychiatrist, emergency department, or hospitalization). Generalized estimating equations were used to compare rates of MHS use. Baseline, peritreatment, and posttreatment MHS use were defined as visits from 2 years to 3 months before, 3 months before to 3 months after, and from 3 months after to 2 years after start of treatment, respectively.
RESULTS
From 2004 to 2013, 4296 patients underwent cystectomy (n = 3332) or curative-intent radiotherapy (n = 964). Compared with baseline, the rate of MHS use was higher in the peritreatment (adjusted rate ratio [aRR] = 1.64, 95% confidence interval [CI] = 1.48 to 1.82) and posttreatment periods (aRR = 1.45, 95% CI =1.30 to 1.63). By 2 years posttreatment, 24.6% (95% CI = 23.4% to 25.9%) of all patients had MHS use. Patients with baseline MHS use had substantially higher MHS use in the peritreatment (aRR = 5.77, 95% CI = 4.86 to 6.86) and posttreatment periods (aRR = 4.58, 95% CI = 3.78 to 5.55). Female patients had higher use MHS use overall, but males had a higher incremental increase in the posttreatment period compared with baseline (2-sided Pinteraction = .02). Male patients had a statistically significant increase in MHS use following surgery or radiotherapy, whereas female patients only had an increase following surgery.
CONCLUSIONS
MHS use is common among patients undergoing treatment for bladder cancer, particularly in the peritreatment period. Screening for mental health concerns in this population is warranted.
Identifiants
pubmed: 33674834
pii: 6154859
doi: 10.1093/jnci/djab026
pmc: PMC8489836
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1238-1245Commentaires et corrections
Type : ErratumIn
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
J Clin Oncol. 2020 Jan 1;38(1):51-62
pubmed: 31714869
Eur Urol Focus. 2020 Nov 15;6(6):1188-1189
pubmed: 30862421
JCO Oncol Pract. 2020 Jul;16(7):409-413
pubmed: 32574130
Br J Cancer. 2019 Jul;121(2):195-196
pubmed: 31178590
BMJ Open. 2014 Jan 29;4(1):e004295
pubmed: 24477317
Eur Urol Focus. 2020 Nov 15;6(6):1155-1157
pubmed: 31542408
Can Urol Assoc J. 2019 Apr;13(4):92-101
pubmed: 30273116
JCO Oncol Pract. 2020 Jul;16(7):422-430
pubmed: 32574128
Cancer. 2010 Sep 1;116(17):4160-7
pubmed: 20681012
Cancer. 2018 Aug 1;124(15):3127-3135
pubmed: 29660813
Circulation. 2016 Feb 9;133(6):601-9
pubmed: 26858290
Am J Prev Med. 2013 Apr;44(4):392-398
pubmed: 23498106
Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):221-8
pubmed: 8083117
J Clin Epidemiol. 1992 Jun;45(6):613-9
pubmed: 1607900
Urology. 2010 Sep;76(3):671-5
pubmed: 20451964
Lancet Oncol. 2010 Aug;11(8):797-804
pubmed: 20599423
Med Care. 2004 Oct;42(10):960-5
pubmed: 15377928
Eur Urol Focus. 2020 Nov 15;6(6):1180-1187
pubmed: 30797737
Urol Oncol. 2019 Feb;37(2):97-107
pubmed: 30584034
J Sex Med. 2020 May;17(5):949-956
pubmed: 32171630
J Clin Oncol. 2002 Dec 1;20(23):4581-90
pubmed: 12454116
Nat Rev Urol. 2014 Aug;11(8):445-53
pubmed: 24980191
J Cancer Surviv. 2007 Jun;1(2):156-60
pubmed: 18648956
Cancer. 2015 Jul 1;121(13):2214-21
pubmed: 25823667
N Engl J Med. 2003 Aug 28;349(9):859-66
pubmed: 12944571
Ann Oncol. 2019 Dec 1;30(12):1914-1924
pubmed: 31613312